Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography (KDTEE)
Heart Valve Disease, Heart Septal Defects, Atrial
About this trial
This is an interventional other trial for Heart Valve Disease focused on measuring Echocardiography, Transesophageal, Dexmedetomidine, Ketamine, Propofol
Eligibility Criteria
Inclusion Criteria:
- Patients with Atrial septal defect/Valvular Heart disease (MS/MR/AS/AR)
Exclusion Criteria:
- Atrial fibrillation with fast ventricular rate
- Congestive cardiac failure
- BMI > 30
- Perforated viscus/active GI bleed
- Esophageal stricture/tumor/laceration
- H/o radiation to neck & mediastinum
- H/o GI surgery or H/o dysphagia
- Restriction of neck mobility
- Active esophagitis/peptic ulcer disease
- Symptomatic bradycardia
- Seizure disorder
- Coagulopathy/thrombocytopenia
Sites / Locations
- Postgraduate Institute of Medical Education and Research
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Group D
Group KF
Dexmedetomidine- drug used for moderate sedation prepared as 200 mic in 20 ml syringe.with intravenous loading dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography
Ketamine+Propofol -drugs used for sedation-as ratio 1:3with 19ml of 1% propofol + 1.3ml ketamine(50mg/ml) as loading intravenous infusion dose at 1ml/kg/hour till required sedation is achieved and maintenance infusion of 0.05mg/kg/hour till completion of transesophageal echocardiography